AntiBERTa, an Antibody-SpecificMachine Learning Model with Multiple Applications
Alchemab Therapeutics announced research on AntiBERTa, a transformer neural network that reads components of antibody amino acid sequences.
alchemab.comCrawled Oct 16, 2026
Alchemab Therapeutics announced research on AntiBERTa, a transformer neural network that reads components of antibody amino acid sequences.
Adaptive immunity represents nature’s most effective search engine: Disease protection arises through a beneficial antibody providing a selective advantage over a myriad of different antibodies.
Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics at Oxford’s BioEscalator redirected their expertise and business plans to develop COVID-19 detection methods and potential therapeutics, collaborating with nearby experts.
Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity.
20 May 2020 – Alchemab’s publication illustrating progress in understanding patients’ immune responses to COVID19 which will help inform vaccination and antibody therapeutics.
Deep sequencing of B cell receptor heavy chains from 31 COVID-19 patients in the UK revealed a stereotypical naive immune response to SARS-CoV-2 across patients. The study also observed B cell clonal expansion, possibly due to memory bystander effects.
The article describes how the U.K. life sciences industry is responding to COVID-19 through collaboration, speed, creativity and resource commitments to develop drugs, vaccines and diagnostics.
Jane Osbourn, Alchemab’s CSO and co-founder, presents on B cell immune repertoires at the Genomics England Research Summit.
Alchemab received a UK Biomedical Catalyst early award grant from Innovate UK to support development of an antibody therapy for Huntington’s disease. The grant supports its collaboration with Medicines Discovery Catapult.
Cambridge, UK, 15 April 2021 – Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
Alchemab Therapeutics, a biotechnology company focused on discovering and developing naturally occurring protective antibodies in neurodegeneration and oncology, appointed Douglas A. Treco, PhD as CEO. Treco will join the board and be based in Boston, Massachusetts.
Alchemab Therapeutics appointed Young T. Kwon, PhD, as Chief Financial and Operating Officer. The company focuses on discovering and developing naturally occurring protective antibodies in neurodegeneration and oncology.
Cambridge, UK, 5 May 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with AstraZeneca to accelerate prostate cancer research.
The page announces the winners of the 2020 OBN Awards, presented on 11 June at the Royal Lancaster in London.
The company develops therapeutics to treat and cure neurodegenerative diseases and cancer.
Donna Finch is Alchemab’s Vice President of Translational and Clinical Science and oversees target discovery and validation, and non-clinical and early clinical development.
Jake Galson is Alchemab’s Vice President of Technology where he leads the development and application of novel technologies for the company.
Jane Osbourn leads Alchemab. She previously served as Vice President of R&D at MedImmune, where she contributed to antibody phage display technology and the development of antibody therapies including HUMIRA and IMFINZI.
Kevin Lee is Chief Executive Officer of Bicycle Therapeutics and a Non-Executive Director of Mestag and NodThera Ltd. At Pfizer, Kevin held responsibility for more than 20 rare disease programs and established Pfizer’s rare disease strategy.
Olivia Cavlan is Alchemab’s Chief Corporate Development and Strategy Officer where she oversees global business development and partnerships and leads corporate strategy.
Paul Varley is the Chief Development Officer and oversees pre-clinical development, toxicology, chemistry manufacturing and control (CMC), and quality.
Alchemab uses patient samples, deep B cell sequencing and computational analysis to identify convergent protective antibody responses among people susceptible but resilient to specific diseases.
The company collaborates with experts in medicine and science to develop therapeutics.
The company lists info@alchemab.com for general inquiries.
Alchemab Therapeutics Ltd is registered in England and Wales under number 12156844 and says it protects personal data collected about website visitors and end customers.
Alchemab Therapeutics appoints Dr. Ben Porter-Brown as chief medical officer (CMO) to advance its pipeline of novel antibody therapeutics. The UK-based biotech firm aims to accelerate clinical development with Porter-Brown’s pharma and biotech leadership experience. The move strengthens Alchemab’s focus on translating its antibody-based treatments into clinical applications.
Alchemab Therapeutics secures a £25 million Series A extension from the British Business Bank, marking the bank’s largest direct investment in a life sciences company. The funding supports expansion of its AI-driven antibody discovery pipeline, aiming to accelerate drug development in the biotech sector.
Cambridge, UK-based **Alchemab Therapeutics** appoints **Ulrich Wendt**, a former Sanofi executive, as its **chief business officer (CBO)**. Wendt joins to strengthen the company’s partnerships with biopharma firms for developing novel antibody therapeutics. The move follows Alchemab’s focus on expanding its pipeline through strategic collaborations.
Alchemab Therapeutics begins a Phase 1 clinical trial of its antibody therapy **ATLX-1282**, licensed to **Eli Lilly** under an exclusive global agreement. The company also extends its **Series A financing** to support further development. ATLX-1282 was previously licensed in May 2025, with Alchemab receiving a milestone payment upon trial initiation.
Alchemab Therapeutics licenses its ATLX-1282 program—a first-in-class, investigational new drug (IND)-ready treatment—to Eli Lilly for neurodegenerative conditions. The deal, valued at $415 million, targets a novel receptor and mechanism not previously explored in therapies. Lilly gains exclusive rights to develop and commercialize the asset under the agreement.
Alchemab Therapeutics partners with Lilly to develop up to five new antibody-based therapies for amyotrophic lateral sclerosis (ALS). The collaboration leverages Alchemab’s proprietary antibody discovery platform to identify potential treatments. Both companies will jointly advance research and development efforts for the novel therapies.
Alchemab Therapeutics names Jane Osbourn, its co-founder and Chief Scientific Officer, as the new Chief Executive Officer. Osbourn succeeds Young Kwon in leading the company, which specializes in discovering therapeutic antibodies from resilient individuals. She joins the Board alongside her new executive role.
Alchemab Therapeutics secures a **$595,000 grant** from The Michael J. Fox Foundation to advance its Parkinson’s disease program. The company identifies naturally occurring antibodies targeting **prostaglandin biology** in Parkinson’s, using its discovery platform. Research will proceed at Alchemab’s Cambridge, UK, facilities with MJFF funding.